false Q3 --12-31 0001424768 0001424768 2026-01-01 2026-09-30 0001424768 2026-11-13 0001424768 2026-09-30 0001424768 2025-12-31 0001424768 us-gaap:NonrelatedPartyMember 2026-09-30 0001424768 us-gaap:NonrelatedPartyMember 2025-12-31 0001424768 us-gaap:RelatedPartyMember 2026-09-30 0001424768 us-gaap:RelatedPartyMember 2025-12-31 0001424768 us-gaap:SeriesCPreferredStockMember 2026-09-30 0001424768 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001424768 us-gaap:SeriesDPreferredStockMember 2026-09-30 0001424768 us-gaap:SeriesDPreferredStockMember 2025-12-31 0001424768 2026-07-01 2026-09-30 0001424768 2025-07-01 2025-09-30 0001424768 2025-01-01 2025-09-30 0001424768 us-gaap:RelatedPartyMember 2026-07-01 2026-09-30 0001424768 us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0001424768 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0001424768 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0001424768 us-gaap:NonrelatedPartyMember 2026-07-01 2026-09-30 0001424768 us-gaap:NonrelatedPartyMember 2025-07-01 2025-09-30 0001424768 us-gaap:NonrelatedPartyMember 2026-01-01 2026-09-30 0001424768 us-gaap:NonrelatedPartyMember 2025-01-01 2025-09-30 0001424768 us-gaap:CommonStockMember 2026-06-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2026-06-30 0001424768 us-gaap:TreasuryStockCommonMember 2026-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001424768 us-gaap:RetainedEarningsMember 2026-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001424768 2026-06-30 0001424768 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2026-07-01 2026-09-30 0001424768 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001424768 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001424768 us-gaap:CommonStockMember 2026-09-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2026-09-30 0001424768 us-gaap:TreasuryStockCommonMember 2026-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001424768 us-gaap:RetainedEarningsMember 2026-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001424768 us-gaap:CommonStockMember 2025-06-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2025-06-30 0001424768 us-gaap:TreasuryStockCommonMember 2025-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001424768 us-gaap:RetainedEarningsMember 2025-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001424768 2025-06-30 0001424768 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2025-07-01 2025-09-30 0001424768 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001424768 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001424768 us-gaap:CommonStockMember 2025-09-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2025-09-30 0001424768 us-gaap:TreasuryStockCommonMember 2025-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001424768 us-gaap:RetainedEarningsMember 2025-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001424768 2025-09-30 0001424768 us-gaap:CommonStockMember 2025-12-31 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2025-12-31 0001424768 us-gaap:TreasuryStockCommonMember 2025-12-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001424768 us-gaap:RetainedEarningsMember 2025-12-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001424768 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2026-01-01 2026-09-30 0001424768 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001424768 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-09-30 0001424768 us-gaap:CommonStockMember 2024-12-31 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2024-12-31 0001424768 us-gaap:TreasuryStockCommonMember 2024-12-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001424768 us-gaap:RetainedEarningsMember 2024-12-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001424768 2024-12-31 0001424768 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001424768 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001424768 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2025-01-01 2025-09-30 0001424768 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001424768 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2026-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2026-01-01 2026-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2026-07-01 2026-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2026-01-01 2026-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2025-07-01 2025-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2025-01-01 2025-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2026-07-01 2026-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2026-01-01 2026-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2025-07-01 2025-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2025-01-01 2025-09-30 0001424768 VYCO:PeterZachariouMember 2026-09-30 0001424768 VYCO:PeterZachariouMember 2025-12-31 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2026-09-30 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2025-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2025-12-31 0001424768 VYCO:InsurancePolicyFinanceAgreementsMember 2026-09-30 0001424768 VYCO:InsurancePolicyFinanceAgreementsMember 2025-12-31 0001424768 VYCO:EconomicInjuryDisasterLoanProgramMember VYCO:CaresActMember 2026-09-30 0001424768 VYCO:EconomicInjuryDisasterLoanProgramMember VYCO:CaresActMember 2025-12-31 0001424768 VYCO:PeterZachariouMember 2018-06-25 0001424768 VYCO:PeterZachariouMember 2018-06-24 2018-06-25 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2022-11-17 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2018-03-26 2022-11-17 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2011-03-25 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:ExtendedMaturityMember 2011-03-25 2011-03-25 0001424768 VYCO:EconomicInjuryDisasterLoanProgramMember VYCO:CaresActMember 2020-07-07 0001424768 VYCO:EconomicInjuryDisasterLoanProgramMember VYCO:CaresActMember 2020-07-06 2020-07-07 0001424768 VYCO:EuroAmericanInvestmentCorpMember VYCO:AmendmentAgreementMember 2018-01-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember VYCO:AmendmentAgreementMember 2026-01-01 2026-09-30 0001424768 VYCO:BusinessSegmentMember 2026-01-01 2026-09-30 0001424768 VYCO:GeographicSegmentsMember 2026-01-01 2026-09-30 0001424768 VYCO:VycorMedicalIncMember 2026-07-01 2026-09-30 0001424768 VYCO:VycorMedicalIncMember 2025-07-01 2025-09-30 0001424768 VYCO:VycorMedicalIncMember 2026-01-01 2026-09-30 0001424768 VYCO:VycorMedicalIncMember 2025-01-01 2025-09-30 0001424768 VYCO:NovaVisionIncMember 2026-07-01 2026-09-30 0001424768 VYCO:NovaVisionIncMember 2025-07-01 2025-09-30 0001424768 VYCO:NovaVisionIncMember 2026-01-01 2026-09-30 0001424768 VYCO:NovaVisionIncMember 2025-01-01 2025-09-30 0001424768 us-gaap:CorporateMember 2026-07-01 2026-09-30 0001424768 us-gaap:CorporateMember 2025-07-01 2025-09-30 0001424768 us-gaap:CorporateMember 2026-01-01 2026-09-30 0001424768 us-gaap:CorporateMember 2025-01-01 2025-09-30 0001424768 VYCO:VycorMedicalIncMember 2026-09-30 0001424768 VYCO:VycorMedicalIncMember 2025-12-31 0001424768 VYCO:NovaVisionIncMember 2026-09-30 0001424768 VYCO:NovaVisionIncMember 2025-12-31 0001424768 us-gaap:SegmentDiscontinuedOperationsMember 2026-09-30 0001424768 us-gaap:SegmentDiscontinuedOperationsMember 2025-12-31 0001424768 country:US 2026-07-01 2026-09-30 0001424768 country:US 2025-07-01 2025-09-30 0001424768 country:US 2026-01-01 2026-09-30 0001424768 country:US 2025-01-01 2025-09-30 0001424768 srt:EuropeMember 2026-07-01 2026-09-30 0001424768 srt:EuropeMember 2025-07-01 2025-09-30 0001424768 srt:EuropeMember 2026-01-01 2026-09-30 0001424768 srt:EuropeMember 2025-01-01 2025-09-30 0001424768 us-gaap:CorporateMember 2026-07-01 2026-09-30 0001424768 us-gaap:CorporateMember 2025-07-01 2025-09-30 0001424768 us-gaap:CorporateMember 2026-01-01 2026-09-30 0001424768 us-gaap:CorporateMember 2025-01-01 2025-09-30 0001424768 country:US 2026-09-30 0001424768 country:US 2025-12-31 0001424768 srt:EuropeMember 2026-09-30 0001424768 srt:EuropeMember 2025-12-31 0001424768 VYCO:FinancialAdvisoryAndInvestmentBankingServicesAgreementMember 2024-08-27 2024-08-27 0001424768 VYCO:FinancialAdvisoryAndInvestmentBankingServicesAgreementMember 2026-07-01 2026-09-30 0001424768 VYCO:FinancialAdvisoryAndInvestmentBankingServicesAgreementMember 2025-07-01 2025-09-30 0001424768 VYCO:FinancialAdvisoryAndInvestmentBankingServicesAgreementMember 2026-01-01 2026-09-30 0001424768 VYCO:FinancialAdvisoryAndInvestmentBankingServicesAgreementMember 2025-01-01 2025-09-30 0001424768 VYCO:SeriesConvertibleCPreferredStockMember 2026-01-01 2026-09-30 0001424768 VYCO:SeriesConvertibleCPreferredStockMember 2026-09-30 0001424768 VYCO:SeriesConvertibleDPreferredStockMember 2026-09-30 0001424768 VYCO:SeriesConvertibleDPreferredStockMember 2026-01-01 2026-09-30 0001424768 VYCO:NonemployeesMember 2026-07-01 2026-09-30 0001424768 VYCO:NonemployeesMember 2025-07-01 2025-09-30 0001424768 VYCO:NonemployeesMember 2026-01-01 2026-09-30 0001424768 VYCO:NonemployeesMember 2025-01-01 2025-09-30 0001424768 VYCO:NonemployeeDirectorsMember 2026-09-30 0001424768 VYCO:NonemployeeDirectorsMember 2025-12-31 0001424768 VYCO:OfficeSpaceMember 2026-01-01 2026-09-30 0001424768 VYCO:OfficeSpaceMember 2026-09-30 0001424768 VYCO:DirectorsMember VYCO:FountainheadMember us-gaap:CommonStockMember 2026-09-30 0001424768 VYCO:DirectorsMember VYCO:FountainheadMember us-gaap:SeriesDPreferredStockMember 2026-09-30 0001424768 VYCO:ChairmanMember VYCO:FountainheadMember us-gaap:CommonStockMember 2026-09-30 0001424768 VYCO:ChairmanMember VYCO:FountainheadMember us-gaap:SeriesDPreferredStockMember 2026-09-30 0001424768 VYCO:FountainheadMember 2026-07-01 2026-09-30 0001424768 VYCO:FountainheadMember 2025-07-01 2025-09-30 0001424768 VYCO:PeterZachariouMember 2026-07-01 2026-09-30 0001424768 VYCO:PeterZachariouMember 2025-07-01 2025-09-30 0001424768 VYCO:FountainheadMember 2026-01-01 2026-09-30 0001424768 VYCO:FountainheadMember 2025-01-01 2025-09-30 0001424768 VYCO:PeterZachariouMember 2026-01-01 2026-09-30 0001424768 VYCO:PeterZachariouMember 2025-01-01 2025-09-30 0001424768 2025-01-01 2025-12-31 0001424768 VYCO:FountainheadMember 2025-01-01 2025-12-31 0001424768 VYCO:PeterZachariouMember 2025-01-01 2025-12-31 0001424768 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001424768 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0001424768 VYCO:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001424768 VYCO:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares VYCO:Integer xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal quarter ended September 30, 2026

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from to

 

VYCOR MEDICAL, INC.

(Exact name of small business issuer as specified in its charter)

 

Delaware   001-34932   20-3369218
(State of   (Commission   (IRS Employer
Incorporation)   File Number)   Identification No.)

 

951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487

(Address of principal executive offices) (Zip code)

 

Issuer’s telephone number: (561) 558-2020

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock   VYCO   OTCQB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-accelerated Filer ☐ (Do not check if a smaller reporting company) Smaller Reporting Company ☒
  Emerging Growth Company ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

There were 33,372,796 shares outstanding of registrant’s common stock, par value $0.0001 per share, as of November 13, 2026.

 

Transitional Small Business Disclosure Format (check one): Yes ☐ No ☒

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  PART I  
     
Item 1. Financial Statements 3
     
  Unaudited Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 3
     
  Unaudited Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2026 and 2025. 4
     
  Unaudited Consolidated Statements of Stockholders’ Deficiency for the three and nine months ended September 30, 2026 and 2025. 5
     
  Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025. 6
     
  Notes to Unaudited Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation 17
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 22
     
Item 4. Controls and Procedures 22
     
  PART II  
     
Item 1. Legal Proceedings 24
     
Item 1A. Risk Factors 24
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
     
Item 3. Defaults Upon Senior Securities 24
     
Item 4. Mine Safety Disclosures 24
     
Item 5. Other Information 24
     
Item 6. Exhibits 24
     
SIGNATURES 25

 

2
 

 

PART 1

ITEM 1. FINANCIAL STATEMENTS

 

VYCOR MEDICAL, INC.

Consolidated Balance Sheets

(Unaudited)

 

   September 30,   December 31, 
   2026   2025 
ASSETS        
Current Assets          
Cash  $199,409   $86,982 
Trade accounts receivable, net   185,617    218,891 
Inventory   165,291    159,202 
Prepaid expenses and other current assets   102,904    97,230 
Current assets of discontinued operations   268    1,117 
Total Current Assets   653,489    563,422 
           
Fixed assets, net   87,326    133,936 
           
Other assets          
Non-current inventory, net   41,213    71,779 
Security deposits   6,000    6,000 
Operating lease - right of use assets   176,851    55,283 
Total Other Assets   224,064    133,062 
TOTAL ASSETS  $964,879   $830,420 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY          
Current Liabilities          
Accounts payable  $96,321   $84,755 
Accrued interest   604,932    569,030 
Accrued interest - Related Party   207,736    245,679 
Accrued liabilities   79,835    89,938 
Dividends payable - Related Party   3,243,700    2,919,330 
Notes payable   340,770    326,978 
Notes payable - Related Party   493,373    493,373 
Current operating lease liabilities   39,687    52,221 
Current liabilities of discontinued operations   537    164 
Total Current Liabilities   5,106,891    4,781,468 
           
Operating lease liability - long term   137,621    - 
Loan payable - SBA EIDL   133,038    135,831 
           
Total Liabilities   5,377,550    4,917,299 
           
STOCKHOLDERS’ DEFICIENCY          
Preferred stock, $0.0001 par value, 10,000,000 shares authorized          
Preferred C Stock, 1 and 1 share issued and outstanding as at September 30, 2026 and December 31, 2025 respectively   -    - 
Preferred D Stock, 270,306 and 270,306 shares issued and outstanding as at September 30, 2026 and December 31, 2025 respectively   27    27 
Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2026 and December 31, 2025; 33,476,130 shares issued and 33,372,796 shares outstanding at September 30, 2026 and December 31, 2025, respectively   3,347    3,347 
Additional Paid-in Capital   29,431,959    29,431,959 
Treasury Stock (103,334 shares of Common Stock as at September 30, 2026 and December 31, 2025 respectively, at cost)   (1,033)   (1,033)
Accumulated Deficit   (33,974,668)   (33,648,856)
Accumulated Other Comprehensive Income   127,697    127,677 
Total Stockholders’ Deficiency   (4,412,671)   (4,086,879)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY  $964,879   $830,420 

 

See accompanying notes to consolidated financial statements

 

3
 

 

VYCOR MEDICAL, INC.

Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

 

             
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2026   2025   2026   2025 
                 
Revenue  $414,895   $513,792   $1,291,699   $1,446,523 
Cost of Goods Sold   61,878    61,860    219,084    220,786 
Gross Profit   353,017    451,932    1,072,615    1,225,737 
                     
Operating Expenses:                    
Research and development   -    -    -    9,963 
Depreciation and amortization   14,880    14,880    43,743    44,641 
Selling, general and administrative   310,713    404,967    948,789    1,100,708 
Total Operating Expenses   325,593    419,847    992,532    1,155,312 
Operating income   27,424    32,085    80,083    70,425 
                     
Other (Expense) Income                    
Interest expense: Related Party   (12,573)   (12,571)   (37,713)   (37,713)
Interest expense: Other   (13,386)   (13,884)   (39,789)   (39,885)
Gain (loss) on foreign currency exchange   56    (640)   (74)   (638)
Total Other (Expense)   (25,903)   (27,095)   (77,576)   (78,236)
                     
Income (Loss) Before Provision for Income Taxes   1,521    4,990    2,507    (7,811)
Provision for income taxes   -    -    -    - 
Net Income (Loss) from continuing operations   1,521    4,990    2,507    (7,811)
Loss from discontinued operations, net of tax   (783)   (54)   (3,949)   (1,929)
Net Income (Loss)   738    4,936    (1,442)   (9,740)
                     
 Preferred stock dividends   (162,185)   (162,185)   (324,370)   (324,370)
Net Loss Available to Common Stockholders  $(161,447)  $(157,249)  $(325,812)  $(334,110)
                     
Other Comprehensive Income (Loss)                    
 Foreign Currency Translation Adjustment   -    -    20    - 
Comprehensive Income (Loss)  $738   $4,936   $(1,422)  $(9,740)
                     
Loss Per Share - basic and diluted                    
Loss from continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Loss from discontinued operations  $(0.00)  $(0.00)  $(0.00)  $(0.00)
Loss available to common stockholders  $(0.00)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted Average Number of Shares Outstanding – Basic and Diluted   33,372,796    33,372,796    33,372,796    33,372,796 

 

See accompanying notes to consolidated financial statements

 

4
 

 

VYCOR MEDICAL, INC.

Consolidated Statements of Stockholders’ Deficiency

(Unaudited)

 

                                   Additional       Accum     
   Common Stock   Preferred C   Preferred D   Treasury Stock   Paid-in   Accumulated  

OCI

    
   Number   Amount   Number   Amount   Number   Amount   Number   Amount   Capital   Deficit   (Loss)   Total 
                                                 
Balance at June 30, 2026   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,813,221)  $127,697   $(4,251,224)
Net income for the three months ended September 30, 2026        -         -         -         -    -    738    -    738 
Preferred stock dividends        -         -         -         -    -    (162,185)       (162,185)
Balance at September 30, 2026   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,974,668)  $127,697   $(4,412,671)

 

                                   Additional       Accum     
   Common Stock   Preferred C   Preferred D   Treasury Stock   Paid-in   Accumulated   OCI    
   Number   Amount   Number   Amount   Number   Amount   Number   Amount   Capital   Deficit   (Loss)   Total 
                                                 
Balance at June 30, 2025   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,428,921)  $127,677   $(3,866,944)
Net income for the three months ended September 30, 2025        -         -         -         -    -    4,936    -    4,936 
Preferred stock dividends        -         -         -         -    -    (162,185)   -    (162,185)
Balance at September 30, 2025   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,586,170)  $127,677   $(4,024,193)

 

                                   Additional       Accum     
   Common Stock   Preferred C   Preferred D   Treasury Stock   Paid-in   Accumulated   OCI    
   Number   Amount   Number   Amount   Number   Amount   Number   Amount   Capital   Deficit   (Loss)   Total 
                                                 
Balance at December 31, 2025   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,648,856)  $127,677   $(4,086,879)
Net loss for the nine months ended September 30, 2026        -         -         -        -    -    (1,442)   -    (1,442)
Foreign currency translation adjustments        -         -         -         -    -    -    20    20 
Preferred stock dividends        -         -         -         -    -    (324,370)   -    (324,370)
Balance at September 30, 2026   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,974,668)  $127,697   $(4,412,671)

 

                                   Additional       Accum     
   Common Stock   Preferred C   Preferred D   Treasury Stock   Paid-in   Accumulated   OCI     
   Number   Amount   Number   Amount   Number   Amount   Number   Amount   Capital   Deficit   (Loss)   Total 
                                                 
Balance at December 31, 2024   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,252,060)  $127,677   $(3,690,083)
Net loss for the nine months ended September 30, 2025        -         -         -         -    -    (9,740)   -    (9,740)
Preferred stock dividends        -         -         -         -    -    (324,370)   -    (324,370)
Balance at September 30, 2025   33,476,130   $3,347    1   $0    270,306   $27    (103,334)  $(1,033)  $29,431,959   $(33,586,170)  $127,677   $(4,024,193)

 

 

See accompanying notes to consolidated financial statements

 

5
 

 

VYCOR MEDICAL, INC.

Consolidated Statements of Cash Flows

(Unaudited)

 

       
   For the nine months ended 
   September 30,   September 30, 
   2026   2025 
Cash flows from operating activities:          
Net loss  $(1,442)  $(9,740)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:          
Depreciation of fixed assets   45,668    46,999 
Allowance for doubtful accounts - accounts receivable   5,560    2,690 
Stock based compensation   -    48,838 
           
Changes in operating assets and liabilities:          
Accounts receivable   27,714    (83,483)
Inventory   24,477    (1,736)
Prepaid expenses   (5,674)   (30,607)
Accrued interest - Related Party   (37,943)   22,713 
Accrued interest   35,901    35,901 
Accounts payable   11,566    (54,748)
Accrued liabilities   (6,584)   (29,858)
Changes in discontinued operations, net   1,222    328 
Cash provided by (used in) operating activities   100,465    (52,703)
Cash flows from investing activities:          
Purchase of fixed assets   (1,882)   (3,619)
Sale and disposal of fixed assets   2,824    842 
Cash provided by (used in) investing activities   942    (2,777)
Cash flows from financing activities:          
Proceeds - Notes Payable Other   58,237    59,024 
Repayments - Notes Payable Other   (47,237)   (44,962)
Cash provided by financing activities   11,000    14,062 
Effect of exchange rate changes on cash   20    - 
Net increase (decrease) in cash   112,427    (41,418)
Cash at beginning of period   86,982    105,648 
Cash at end of period  $199,409   $64,230 
           
Supplemental Disclosures of Cash Flow information:          
Cash paid for interest  $79,544   $19,883 
Cash paid for income tax  $-   $- 
Non-Cash Activities          
Non-cash accrued dividends  $324,370   $324,370 
Right-of-use asset added for operating lease under lease modification  $158,265   $- 

 

See accompanying notes to consolidated financial statements

 

6
 

 

VYCOR MEDICAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

(Unaudited)

 

1. BASIS OF PRESENTATION

 

The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2025 derives from the audited financial statements at that date but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

The unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2026 and 2025, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

Ability to continue as a Going Concern

 

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $1,442 for the nine months ended September 30, 2026 and has not generated sufficient positive cash flows from operations. As of September 30, 2026 the Company had a working capital deficiency of $4,453,402 which includes related party liabilities of $3,944,809. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

The Company is executing on a plan to achieve a reduction in operating losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $604,932 which has a maturity date of December 31, 2026, having been extended on a number of occasions from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond December 31, 2026 will be available. However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2027 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

 

2. SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation

 

The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.

 

Recent Accounting Pronouncements

 

From time-to-time new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that may have an impact on the Company’s accounting and reporting. Unless otherwise discussed, the Company believes that other recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

 

7
 

 

Recently adopted accounting pronouncements

 

Income Taxes

 

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 is intended to improve income tax disclosures primarily through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024, and early adoption is permitted. We adopted this ASU retrospectively on December 31, 2024. The adoption of ASU 2023-09 did not have a significant impact on the Company’s consolidated financial statements and related disclosures.

 

Financial Instruments – Measurement of Credit Losses for Accounts Receivable and Contract Assets

 

In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendments in this update provide a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current classified accounts receivable and contract assets. This update is effective for annual periods beginning after December 15, 2025, including interim periods within those fiscal years. Adoption of this ASU can be applied prospectively for reporting periods after its effective date. Early adoption is permitted. We adopted this ASU on a prospective basis effective January 1, 2026 and did elect the practical expedient permitted under this ASU. The adoption did not have a material impact on our consolidated financial statements.

 

Recently issued accounting pronouncements not yet adopted

 

Disaggregation of Income Statement Expenses

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying any relevant income statement expense caption. The prescribed categories include, among other things, purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Additionally, entities must disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and for interim reporting periods within fiscal years beginning after December 15, 2027. The guidance can be applied prospectively with an option for retrospective application. Early adoption is also permitted. The Company is currently evaluating the impact of ASU No. 2024-03, if any, upon adoption on January 1, 2027.

 

Interim Reporting: Narrow-Scope Improvements

 

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The ASU clarifies interim disclosure requirements and the applicability of Topic 270. The objective of the amendments is to provide further clarity about the current interim disclosure requirements. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Adoption of this ASU can be applied either a prospective or a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

 

Codification Improvements

 

In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. The ASU addresses thirty-three items, representing the changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. Generally, the amendments in this Update are not intended to result in significant changes for most entities. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026. The adoption method of this ASU may vary, on an issue-by-issue basis. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

 

8
 

 

Revenue Recognition

 

Vycor Medical generates revenue from the sale of its surgical access system to hospitals and other medical professionals. Vycor Medical records revenue from product sales when obligations under the terms of a contract with customers are satisfied. Generally, this occurs with the transfer of control of the goods to customers. Vycor Medical does not provide for product returns or warranty costs.

 

Vycor determines revenue recognition through the following steps:

 

  ● Identification of the contract, or contracts, with a customer
     
  ● Identification of the performance obligations in the contract
     
  ● Determination of the transaction price
     
  ● Allocation of the transaction price to the performance obligations in the contract
     
  ● Recognition of revenue when Vycor satisfy a performance obligation

 

NovaVision generates revenues from various programs, therapy services and other sources such as software license sales. Therapy services revenues represent fees from NovaVision’s vision restoration therapy software, eye movement training software, diagnostic software, clinic set up and training fees, and the professional and support services associated with the therapy. NovaVision provides vision restoration therapy directly to patients. The typical therapy program consists of NeuroEyeCoach, performed over 2-4 weeks, and six modules of Vision Restoration Therapy, performed over 6 months. A patient contract comprises set-up fees and monthly therapy fees. Set-up fees are recognized at the outset of the contract and therapy revenue is recognized ratably over the therapy period. Patient therapy is restricted to being completed by a patient within a specified time frame.

 

Contract liabilities (deferred revenue) results from patients paying for the therapy in advance of receiving the therapy.

 

The Company disaggregates its revenue by division – Vycor and NovaVision – and by geography – United States and Europe – and presents the disaggregation in Note 7.

 

Net Income (Loss) Per Share

 

Basic net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to increase a net income per share or reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented of net loss because the assumed conversion of preferred stock and debt would be anti-dilutive.

 

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share where a net loss is reported:

  

  

Three and nine months ended

September 30, 2026

  

Three and nine months ended

September 30, 2025

 
Debentures convertible into common stock   4,309,198    4,080,627 
Preferred shares convertible into common stock   1,272,052    1,272,052 
Total   5,581,250    5,352,679 

 

9
 

 

3. DISCONTINUED OPERATIONS

 

In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; effective July 1, 2020, Vycor entered into a license agreement with a German-based partner. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of the German operations, which are non-material, until such a time as NovaVision GmbH will be formally wound up.

 

Reconciliation of the significant line items from discontinued operations that are presented in the unaudited consolidated balance sheets and unaudited consolidated statements of comprehensive income (loss) are as follows:

  

Significant line items constituting assets and liabilities in the unaudited consolidated balance sheets

 

   September 30,   December 31, 
   2026   2025 
ASSETS          
Current Assets          
Cash  $268   $1,117 
Total Current Assets   268    1,117 
           
TOTAL ASSETS  $268   $1,117 
           
LIABILITIES          
Current Liabilities          
Accounts payable  $4   $4 
Other current liabilities   533    160 
Total Current Liabilities  $537   $164 

 

Significant line items constituting income (loss) from discontinued operations

 

             
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2026   2025   2026   2025 
                 
Revenue  $-   $-   $-   $- 
Cost of Goods Sold   -    -    -    - 
Gross Profit   -    -    -    - 
                     
Operating Expenses:                    
Selling, general and administrative   783    54    3,962    1,780 
Total Operating Expenses   783    54    3,962    1,780 
Operating Loss   (783)   (54)   (3,962)   (1,780)
                     
Other Income (Expense)                    
Gain (loss) on foreign currency exchange   -    -    13    (149)
Total Other Income (Expense)   -    -    13    (149)
                     
Loss Before Provision for Income Taxes   (783)   (54)   (3,949)   (1,929)
Provision for income taxes   -    -    -    - 
Loss from discontinued operations, net of tax  $(783)  $(54)  $(3,949)  $(1,929)

 

10
 

 

4. NOTES PAYABLE

 

Related Parties Notes Payable

 

Related Party Notes Payable consists of:

 

   September 30, 2026   December 31, 2025 
On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2027 or on demand by the Payee.  $30,000   $30,000 
Between March 26, 2018 and November 17, 2022 the Company issued fifteen promissory notes to Fountainhead Capital Management Limited for $463,373. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. All the notes have been extended on their due dates for another twelve months. The Notes will be due between December 2026 and November 2027 or on demand by the Payee.   463,373    463,373 
Total Related Party Notes Payable  $493,373   $493,373 

 

Other Notes Payable

 

Other Notes Payable consists of:

 

   September 30, 2026   December 31, 2025 
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note’s most recent due date, the note was amended and extended to December 31, 2026. See further note* below.  $300,000   $300,000 
Insurance policy finance agreements and current portion of EIDL Loan (see Long-Term Notes Payable and further note ** below)   40,770    26,978 
Total Other Notes Payable  $340,770   $326,978 

 

Long-Term Notes Payable consists of:

 

   September 30, 2026   December 31, 2025 
On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $150,000 loan under the Economic Injury Disaster Loan Program (EIDL) pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act (“Loan”). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of six and six-quarters percent (3.75%) per annum, with monthly payments in the amount of $731 per month commencing July 7, 2021 and is secured by essentially all of the assets of the Company. The proceeds of the Loan have been used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.  $133,038   $135,831 
Total Long-term Notes Payable  $133,038   $135,831 

 

  * In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $300,000 loan note (the “Note”). Under the Amendment, the Note was extended and the conversion terms of the Note were reduced to $0.21. Conversion of the Note and accrued interest would result in the issuance of 4,309,198 shares of Common Stock as of September 30, 2026. Notwithstanding, EuroAmerican agreed that the Note could not be converted without first offering the Company the right to redeem the Note at principal and accrued interest, and secondly Fountainhead the right to purchase the Note, which cannot be converted prior to such offer and the failure of the Company and Fountainhead to exercise such option in accordance with the amendment terms. The amendment was recognized as a modification, based on the guidance in ASC 470-50. No other term was amended on the Note.

 

  ** The Company routinely finances all their insurance policies through a third-party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

 

11
 

 

5. INVENTORY

 

   September 30, 2026   December 31, 2025 
Current Inventory          
Raw materials and work in process  $58,819   $56,088 
Finished goods   106,472    103,114 
Total Current Inventory  $165,291   $159,202 
           
Non-Current Inventory          
Raw materials and work in process  $27,275   $49,365 
Finished goods   42,364    39,539 
Total   69,639    88,904 
Less: obsolescence provision - finished goods   (28,426)   (17,125)
Total Non-Current Inventory  $41,213   $71,779 

 

The Company estimates the consumption of inventories and separates the inventories that may be consumed after 12 months as non-current inventory.

 

6. LEASE

 

The Company recognized the following related to a lease in its unaudited consolidated balance sheets at September 30, 2026 and December 31, 2025:

 

   September 30, 2026   December 31, 2025 
         
Operating Lease ROU Assets  $176,851   $55,283 
           
Operating Lease Liabilities          
Current portion  $39,687   $52,221 
Long-term portion   137,621    - 
Operating Lease Liabilities  $177,308   $52,221 

 

12
 

 

7. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

 

(a) Business segments

 

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury and which includes Sight Science. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the disaggregated revenues, cost of revenues, gross profits, operating income (loss) and total assets for each segment. Our Chief Executive Officer, as the CODM, organizes our company, manages resource allocations and measures performance among the two operating and reportable segments. Our CODM does not evaluate operating segments using asset or liability information. The CODM uses gross profit to allocate operating and capital resources and assesses performance of each segment by comparing actual gross profit results to historical results and previously forecasted financial information.

 

   2026   2025   2026   2025 
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2026   2025   2026   2025 
Revenue:                
Vycor Medical  $402,048   $492,102   $1,243,713   $1,392,410 
NovaVision   12,847    21,690    47,986    54,113 
Revenue  $414,895   $513,792   $1,291,699   $1,446,523 
Cost of Revenue:                   
Vycor Medical 

$

60,870

  

$

60,875

  

$

216,270

  

$

217,602

 
NovaVision   

1,008

    

985

    

2,814

    

3,184

 
Cost of Revenue  $

61,878

   $

61,860

   $

219,084

   $

220,786

 
Gross Profit                    
Vycor Medical  $341,178   $431,227   $1,027,443   $1,174,808 
NovaVision   11,839    20,705    45,172    50,929 
Gross Profit  $353,017   $451,932   $1,072,615   $1,225,737 
                     
Operating Income (Loss)                    
Vycor Medical  $118,202   $147,394   $364,082   $417,614 
NovaVision   (52,980)   (44,695)   (150,593)   (129,957)
Corporate   (37,798)   (70,614)   (133,406)   (217,232)
Operating Income (Loss)  $27,424   $32,085   $80,083   $70,425 

 

   September 30,   December 31, 
   2026   2025 
Total Assets:          
Vycor Medical  $913,358   $778,216 
NovaVision   51,253    51,087 
Discontinued operations   268    1,117 
Total Assets  $964,879   $830,420 

 

13
 

 

(b) Geographic segments

 

The Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the disaggregated revenues, cost of revenues, gross profits, operating income (loss) and total assets for each segment.

 

   2026   2025   2026   2025 
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2026   2025   2026   2025 
Revenue:                
United States  $413,877   $511,954   $1,286,405   $1,443,940 
Europe   1,018    1,838    5,294    2,583 
Revenue  $414,895   $513,792   $1,291,699   $1,446,523 
Cost of Revenue:                    
United States 

$

61,817

   $

61,823

   $

218,938

   $

220,725

 
Europe   

61

    

37

    

146

    

61

 
Cost of Revenue 

$

61,878

   $

61,860

   $

219,084

   $

220,786

 
Gross Profit                    
United States  $352,060   $450,131   $1,067,467   $1,223,215 
Europe   957    1,801    5,148    2,522 
Gross Profit  $353,017   $451,932   $1,072,615   $1,225,737 
                     
Operating Income (Loss)                    
United States  $71,234   $109,160   $226,073   $307,302 
Europe   (6,012)   (6,461)   (12,584)   (19,645)
Corporate   (37,798)   (70,614)   (133,406)   (217,232)
Operating Income (Loss)  $27,424   $32,085   $80,083   $70,425 

 

   September 30,   December 31, 
   2026   2025 
Total Assets:          
United States  $957,646   $818,237 
Europe   6,965    11,066 
Discontinued operations   268    1,117 
Total Assets  $964,879   $830,420 

 

8. EQUITY

 

Equity Transactions

 

During each of the three and nine months ended September 30, 2026 and 2025, the Company accrued $162,185 and $324,370 of dividends in respect of Company Series D Convertible Preferred shares (see Note 12).

 

On August 27, 2024 Vycor issued 813,971 shares of Company Common Stock (valued at $73,257) to Maxim Group LLC (“Maxim”) pursuant to a financial advisory and investment banking services agreement, to be amortized over twelve months. The amortization for the three months ended September 30, 2026 and 2025 was $0 and $12,209, respectively, and for the nine months ended September 30, 2026 and 2025 was $0 and $48,838, respectively. (see Note 9 and Note 11).

 

Equity Classes

 

Our authorized capital stock consists of 55,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, the rights and preferences of which may be established from time to time by our board. As of September 30, 2026 and December 31, 2025, there were 33,372,796 shares of common stock, one (1) share of Series C Preferred Stock and 270,306 shares of Series D Preferred Stock outstanding.

 

14
 

 

Holders of our common stock are entitled to one vote for each share on all matters voted upon by our stockholders, including the election of directors, and do not have cumulative voting rights. Subject to the rights of holders of any then outstanding shares of our preferred stock, our common stockholders are entitled to any dividends that may be declared by our board. Holders of our common stock are entitled to share rateably in our net assets upon our dissolution or liquidation after payment or provision for all liabilities and any preferential liquidation rights of our preferred stock then outstanding. Holders of our common stock have no pre-emptive rights to purchase shares of our stock. The shares of our common stock are not subject to any redemption provisions and are not convertible into any other shares of our capital stock. All outstanding shares of our common stock are, and the shares of common stock to be issued will be, upon payment therefor, fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock will be subject to those of the holders of any shares of our preferred stock we may issue in the future.

 

Series C Convertible Preferred Stock shares (“Preferred C Stock”) are convertible (at the Holder’s option or mandatorily upon the occurrence of certain events) into 14,815 shares of the Company’s Common Stock (at $3.75 per share). The Preferred C Stock carries no dividend or other rights.

 

Series D Convertible Preferred Stock shares (“Preferred D Stock”) are convertible into Company Common Shares at a price of $2.15. The Series D carry a cumulative preferred dividend of 12% per annum, payable in cash semi-annually in February and August of each year. The Company is able to redeem the Series D at par at any time, at its sole option.

 

9. STOCK-BASED COMPENSATION

 

The Company from time-to-time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model, or their contractual value if different in the case of common stock. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.

 

Non-Employee Stock Compensation

 

Aggregate stock-based compensation for shares of common stock granted to non-employees for each of the three months ended September 30, 2026 and 2025 was $0 and $12,209 respectively; and for each of the nine months ended September 30, 2026 and 2025 was $0 and $48,838 respectively. As of September 30, 2026 and December 31, 2025, there was $0 of total unrecognized compensation costs related to stock awards (see Note 8 and Note 11).

 

10. COMMITMENTS AND CONTINGENCIES

 

Lease

 

The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $4,300 per month, plus other charges of approximately $2,700 per month. The current lease terminates on December 31, 2026 and was extended for another 39 months to March 31, 2030 in July 2026. The monthly rental payment will increase by 3% each year during 2027 to 2030. The Company accounted for this amendment as a lease modification and remeasured the ROU asset and operating lease liability on the effective date of July 9, 2026. In connection with the lease modification, the Company recorded an additional ROU asset and operating lease liability of $158,265, respectively at the lease amendment date. The discount rate used to determine the present value in this remeasurement is the incremental borrowing rate, estimated to be 5%, as the interest rate implicit in our lease is not readily determinable.

 

Rent expense for the three months ended September 30, 2026 and 2025 was $20,615 and $20,765 respectively and for the nine months ended September 30, 2026 and 2025 was $63,177 and $61,743 respectively. As of September 30, 2026 and December 31, 2025, the weighted-average remaining lease term of the operating lease was 3.5 years and 1 year, respectively, and weighted-average discount rate was 5% respectively.

 

The following table summarizes maturities of operating lease liabilities based on lease terms as of September 30, 2026:

 

      
2026 (remaining period)  $13,679 
2027   48,469 
2028   54,915 
2029   61,705 
2030   15,889 
Total lease payments   194,657 
Less: Imputed interest   (17,349)
Present value of lease liabilities  $177,308 

 

Supplemental cash flow information related to lease where the Company was the lessee for the nine months ended September 30, 2026 and 2025.

   2026   2025 
  

For the nine months ended

September 30,

 
   2026   2025 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflows from operating leases  $39,976   $38,811 

 

15
 

 

11. CONSULTING AND OTHER AGREEMENTS

 

The following agreements were entered into or remained in force during the periods ended September 30, 2026 and 2025:

 

On August 27, 2024 Vycor entered into a financial advisory and investment banking services agreement (“Agreement”) with Maxim. Under the terms of the Agreement, Maxim will assist Vycor in its strategy to grow the Company through strategic acquisitions and assist the Company with efforts to position itself for a potential uplisting to a US exchange. Vycor issued 813,971 shares of Company Common Stock (valued at $73,257) and additional fees would be payable under the agreement subject to the closing of acquisitions or other investment banking transactions. The amortization for the three months ended September 30, 2026 and 2025 was $0 and $12,209, respectively, and for the nine months ended September 30, 2026 and 2025 was $0 and $48,838, respectively. (see Note 8 and Note 9).

 

12. RELATED PARTY TRANSACTIONS AND BALANCES

 

Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at September 30, 2026, 60.95% of the Company’s Common Stock and 69.69% of the Company’s Series D Preferred Stock. Peter Zachariou owns 0.15% of the Company’s Common Stock and 25.71% of the Company’s Series D Preferred Stock. Adrian Liddell, Chairman is a consultant to Fountainhead.

 

During each of the three months ended September 30, 2026 and 2025, the Company accrued an aggregate of $162,185 of Preferred D Stock dividends, of which $113,018 was regarding Fountainhead and $41,693 was regarding Peter Zachariou. During each of the nine months ended September 30, 2026 and 2025, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,036 was regarding Fountainhead and $83,386 was regarding Peter Zachariou. Total accrued Preferred D Stock dividends at September 30, 2026 and December 31, 2025 was $3,243,700 and $2,919,330, respectively, of which $2,260,368 and $2,034,332, respectively, was regarding Fountainhead and $833,859 and $750,473, respectively, was regarding Peter Zachariou.

 

During the three months ended September 30, 2026 and 2025 the Company accrued interest on related party loans of $12,573 and $12,571, respectively and paid interest on related party loans of $30,485 and $15,000, respectively.

 

During the nine months ended September 30, 2026 and 2025 the company accrued interest on related party loans of $37,713, respectively and paid interest on related party loans of $75,656 and $15,000, respectively.

 

13. CONCENTRATION

 

Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.

 

Accounts Receivable Concentration

 

AR Concentration:

 

   September 30,   December 31, 
AR Concentration:  2026   2025 
         
Number of customers over 10%   2    1 
Percentage of accounts receivable   25%   12%

 

The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis, purchases from each manufacturer represent over 10% of total annual purchases.

 

16
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward Looking Statements

 

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PLSRA”), Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding Vycor Medical, Inc. (the “Company” or “Vycor,” also referred to as “us”, “we” or “our”). Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties. Forward-looking statements include statements regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in our industries, (d) our future financing plans and (e) our anticipated needs for working capital. They are generally identifiable by use of the words “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business,” as well as in this Form 10-Q generally. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

 

Any or all of our forward-looking statements in this report may turn out to be inaccurate. They can be affected by inaccurate assumptions we might make or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” and matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future events, or otherwise. We intend that all forward-looking statements be subject to the safe harbor provisions of the PSLRA.

 

17
 

 

1. Organizational History

 

The Company was formed as a limited liability company under the laws of the State of New York on June 17, 2005 as “Vycor Medical LLC”. On August 14, 2007, we converted into a Delaware corporation and changed our name to “Vycor Medical, Inc.” (“Vycor”). The Company’s listing went effective on February 2009 and on November 29, 2010 Vycor completed the acquisition of substantially all of the assets of NovaVision, Inc. (“NovaVision”) and on January 4, 2012 Vycor, through its wholly-owned NovaVision subsidiary, completed the acquisition of all the shares of Sight Science Limited (“Sight Science”), a previous competitor to NovaVision.

 

2. Overview of Business

 

Vycor is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and operates two distinct business units within the medical device industry. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Both businesses adopt a minimally or non-invasive approach. The Company leverages joint resources across the divisions to operate in a cost-efficient manner.

 

Vycor Medical

 

Vycor Medical designs, develops and markets medical devices for use in neurosurgery. Vycor Medical’s ViewSite Brain Access System (“VBAS”) is a next generation retraction and access system. Vycor Medical is ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) certified, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (MDD Class III) for brain and spine surgeries, and regulatory approvals in other international markets.

 

NovaVision

 

NovaVision provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury.

 

Strategy

 

The Company is continuing to execute on a plan to achieve revenue growth. The strategy for Vycor Medical includes: increasing market penetration in the US; increasing international growth in territories where we are not represented or under-represented; continued new product development in response to market demands and demonstrating applicability in a broader range of pathologies; and adding products complementary to VBAS where the Company is able to leverage its existing distribution network.

 

Given NovaVision’s resources, and the large size and diversity of its end markets, we believe that the most efficient way to tackle the distribution of its patient and professional products is by partnering with entities that have either direct access to the end users or the technological capability to leverage the NovaVision therapy platform, particularly in digital health and into non-medical areas. Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

 

18
 

 

Comparison of the Three Months Ended September 30, 2026 to the Three Months Ended September 30, 2025

 

Revenue and Gross Margin:

 

   Three months ended 
   September 30, 
   2026   2025   % Change 
Revenue:            
Vycor Medical  $402,048   $492,102    -18%
NovaVision   12,847    21,690    -41%
   $414,895   $513,792    -19%
Gross Profit               
Vycor Medical  $341,178   $431,227    -21%
NovaVision   11,839    20,705    -43%
   $353,017   $451,932    -22%
                
Gross Margin               
Vycor Medical   85%   88%   -3%
NovaVision   92%   95%   -3%
    85%   88%   -3%

 

Vycor Medical recorded revenue of $402,048 from the sale of its products for the three months ended September 30, 2026, a decrease of $90,054, or 18%, over the same period in 2025. Vycor experienced higher than normal US sales during the 2025 period from new hospitals and bulk orders from some existing hospitals which largely accounts for the decrease in 2026, offset by increased international sales. Gross margin of 85% and 88% was recorded for the three months ended September 30, 2026 and 2025, respectively.

 

NovaVision recorded revenues of $12,847 for the three months ended September 30, 2026, a decrease of $8,843, or 41%, over the same period in 2025. Gross margin was 92% for the three months ended September 30, 2026, compared to 95% for the same period in 2025.

 

Research & Development:

 

Research & Development expenses were $0 for the three months ended September 30, 2026 and September 30, 2025.

 

Selling, General and Administrative Expenses:

 

Selling, general and administrative expenses decreased by $94,254 to $310,713 for the three months ended September 30, 2026 from $404,967 for the same period in 2025. Included within Selling, General and Administrative Expenses are non-cash charges for stock-based compensation as the result of amortizing non-employee shares which have been issued by the Company. The charge for the three months ended September 30, 2026 was $0, a $12,209 decrease from the charge in 2025 due to amortization of the Maxim financial advisory agreement in 2025. Also included within Selling, General and Administrative Expenses are Sales Commissions, which decreased by $57,489 from $101,490 in 2025 to $44,001 in 2026 as a result of lower US sales.

 

The remaining Selling, General and Administrative expenses decreased by $24,556 from $291,268 in 2025 to $266,712 in 2026, as set out in the table below. Investor relations expense relates to a investor and public awareness campaign run by the company.

 

Payroll  $12,706 
Patent fees   (13,617)
Investor relations   (21,425)
Other   (2,220)
Total change  $(24,556)

 

Interest Expense:

 

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the three months ended September 30, 2026 and 2025 was $12,573 and $12,571. Other Interest expense for the three months ended September 30, 2026 and 2025 was $13,386 and $13,884.

 

Loss from Discontinued Operations:

 

Loss from Discontinued Operations in the three months ended September 30, 2026 was $(783) compared to $(54) in 2025; the Company has some minor ongoing costs related to the wind-down of the discontinued operations in Germany but no revenues.

 

19
 

 

Comparison of the Nine months Ended September 30, 2026 to the Nine months Ended September 30, 2025

 

Revenue and Gross Margin:

 

   Nine months ended 
   September 30, 
   2026   2025   % Change 
Revenue:            
Vycor Medical  $1,243,713   $1,392,410    -11%
NovaVision  47,986   54,113    -11%
   $1,291,699   $1,446,523    -11%
Gross Profit               
Vycor Medical  $1,027,443   $1,174,808    -13%
NovaVision  45,172   50,929    -11%
   $1,072,615   $1,225,737    -12%
                
Gross Margin               
Vycor Medical   83%   84%   -1%
NovaVision   94%   94%   0%
    83%   85%   -2%

 

Vycor Medical recorded revenue of $1,243,713 from the sale of its products for the nine months ended September 30, 2026, a decrease of $148,697, or 11%, over the same period in 2025. Vycor experienced higher than normal US sales during the 2025 period from new hospitals and bulk orders from some existing hospitals which largely accounts for the decrease in 2026, together with a slight decrease in international sales. Gross margin of 83% and 84% was recorded for the nine months ended September 30, 2026 and 2025, respectively.

 

NovaVision recorded revenues of $47,986 for the nine months ended September 30, 2026, a decrease of $6,127 over the same period in 2025. Gross margin was 94%, for the periods in 2026 and 2025.

 

Research & Development:

 

Research & Development expenses were $0 for the nine months ended September 30, 2026 compared to $9,963 for the same period in 2025, reflected new product development in the Vycor Medical division in 2025.

 

Selling, General and Administrative Expenses:

 

Selling, general and administrative expenses decreased by $151,919 to $948,789 for the nine months ended September 30, 2026 from $1,100,708 for the same period in 2025. Included within Selling, General and Administrative Expenses are non-cash charges for stock-based compensation as the result of amortizing non-employee shares which have been issued by the Company. The charge for the nine months ended September 30, 2026 was $0, a decrease of $48,838 from $48,838 in 2025 primarily due to amortization of the Maxim financial advisory agreement in 2025. Also included within Selling, General and Administrative Expenses are Sales Commissions, which decreased by $79,570 from $225,665 in 2025 to $146,095 in 2026 reflecting lower US sales.

 

The remaining Selling, General and Administrative expenses decreased by $23,511 from $826,205 in 2025 to $802,694 in 2026 as follows:

 

Payroll  $21,679 
Software development expense   9,204 
Regulatory fees   8,471 
Patent fees   (32,202)
Investor relations   (33,042)
Other   2,379 
   $(23,511)

 

20
 

 

Interest Expense:

 

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the nine months ended September 30, 2026 and 2025 was $37,713 for both periods. Other Interest expense for the nine months ended September 30, 2026 was $39,789 compared to $39,885 for 2025.

 

Loss from Discontinued Operations:

 

Loss from Discontinued Operations increased by $2,020 to $3,949 in 2026 from $1,929 in 2025; the Company has some minor ongoing costs related to the wind-down of the discontinued operations in Germany but no revenues.

 

Liquidity

 

The following table shows liquidity data as of September 30, 2026 and December 31, 2025:

 

   September 30, 2026   December 31, 2025   $ Change 
Cash  $199,409   $86,982   $112,427 
Accounts receivable, inventory and other current assets  $454,080   $476,440   $(22,360)
Total current liabilities  $(5,106,891)  $(4,781,468)  $(325,423)
Working capital deficit  $(4,453,402)  $(4,218,046)  $(235,356)

 

The following table shows cash flow for the periods ended September 30, 2026 and 2025:

 

   September 30, 2026   September 30, 2025   $ Change 
Cash provided by (used in) operating activities  $100,465   $(52,703)  $153,168 
Cash provided by (used in) investing activities  $942   $(2,777)  $3,719 
Cash provided by financing activities  $11,000   $14,062   $(3,062)
Net increase (decrease) in cash  $112,427   $(41,418)  $153,845 

 

Operating Activities. Cash provided by (used in) operating activities comprises net loss adjusted for non-cash items and the effect of changes in working capital and other activities.

 

The following table shows the principal components of cash provided by (used in) operating activities during the nine months ended September 30, 2026 and 2025, with a commentary of changes during the periods and known or anticipated future changes:

 

   September 30, 2026   September 30, 2025   $ Change 
Net loss  $(1,442)  $(9,740)  $8,298 
                
Adjustments to reconcile net loss to cash provided by (used in) operating activities:               
Depreciation of fixed assets  $45,668   $46,999   $(1,331)
Allowance for doubtful accounts - accounts receivable  $5,560   $2,690   $2,870 
Stock based compensation  $-   $48,838   $(48,838)
   $51,228   $98,527   $(47,299)
                
Changes in operating assets and liabilities               
Accounts receivable  $27,714   $(83,483)  $111,197 
Accounts payable and accrued liabilities  $4,982   $(84,606)  $89,588 
Inventory  $24,477   $(1,736)  $26,213 
Prepaid expenses  $(5,674)  $(30,607)  $24,933 
Accrued interest  $(2,042)  $58,614   $(60,656)
Changes in discontinued operations, net  $1,222   $328   $894 
   $50,679   $(141,490)  $192,169 
                
Cash provided by (used in) operating activities  $100,465   $(52,703)  $153,168 

 

21
 

 

Investing Activities. There was $942 provided by investing activities during the nine months ended September 30, 2026 due to purchase of chin rest for $1,882 and sale of chin rests for $1,024 and a reduction of $1,800 due to an adjustment to molds. There was $2,777 cash used in investing activities during the nine months ended September 30, 2025 due to purchase of chin rests of $3,619, offset by sales of fixed assets (chinrests) of $842. The Company anticipates limited investing activities during the next twelve months.

 

Financing Activities. During the nine months ended September 30, 2026, the Company received proceeds of $58,237 and repaid loans primarily related to insurance of $47,237. During the nine months ended September 30, 2025 the Company received insurance financing proceeds of $59,024 and made repayments of $44,962 primarily related to insurance.

 

Liquidity and Plan of Operations, Ability to Continue as a Going Concern

 

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $1,442 for the nine months ended September 30, 2026 and has not generated sufficient positive cash flows from operations. As of September 30, 2026 the Company had a working capital deficiency of $4,453,402 which includes related party liabilities of $3,944,809. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

The Company is executing on a plan to achieve a reduction in operating losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $604,932 which has a maturity date of December 31, 2026, having been extended on a number of occasions from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond December 31, 2026 will be available. However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2027 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

 

Critical Accounting Policies and Estimates

 

The Company’s unaudited consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of its unaudited consolidated financial statements and related disclosures requires it to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in the Company’s unaudited consolidated financial statements. The Company bases its estimates on historical experience, known trends and events and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.

 

Our senior management has reviewed the critical accounting policies and estimates with our Board of Directors. For a description of the Company’s critical accounting policies and estimates, refer to “Part II—Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 31, 2026. Critical accounting policies are those that are most important to the portrayal of our financial condition, results of operations and cash flows and require management’s most difficult, subjective and complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. If actual results were to differ significantly from estimates made, the reported results could be materially affected. There were no significant changes to our critical accounting policies and estimates during the three and nine months ended September 30, 2026.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable

 

ITEM 4. CONTROLS AND PROCEDURES

 

(a) Disclosure Controls and Procedures

 

We are required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (also our principal executive officer) and our chief financial officer (also our principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

 

22
 

 

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company’s management, including the Company’s Chief Executive Officer (“CEO”) (the Company’s principal executive officer) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our CEO and our CFO have concluded that our disclosure controls and procedures were not effective as of September 30, 2026, due to a material weakness in internal control over financial reporting resulting from the resignation of the independent members of the Company’s Audit Committee on April 1, 2021. Consequently, from April 1, 2021 and through September 30, 2026, our disclosure and controls were not effective to ensure that information required to be disclosed by the Company in the reports its files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its CEO and its CFO, as appropriate, to allow timely decisions regarding required disclosure.

 

The matter involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were a lack of a functioning audit committee with independent members, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

 

Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

 

(b) Changes in Internal Controls

 

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

The Company’s management, including the Company’s CEO and CFO, does not expect that the Company’s internal control over financial reporting will prevent all errors and all fraud. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.

 

23
 

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS

 

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of November 13, 2026, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None

 

Index to Exhibits

 

31.1   Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

24
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 13, 2026

 

  Vycor Medical, Inc.
  (Registrant)
     
  By: /s/ Peter C. Zachariou
    Peter C. Zachariou
    Chief Executive Officer and Director
    (Principal Executive Officer)
     
  Date November 13, 2026
     
  By: /s/ Adrian Liddell
    Adrian Liddell
    Chairman of the Board and Director
    (Principal Financial and Accounting Officer)
     
  Date November 13, 2026

 

25